Cantor Fitzgerald预测 Travere治疗学在2026财政年度将获得1.86 EPS, Cantor Fitzgerald predicts Travere Therapeutics will have a $1.86 EPS for FY2026, despite recent financial struggles.

Cantor Fitzgerald预测 Travere治疗学在2026财政年度将获得1.86 EPS, Cantor Fitzgerald predicts Travere Therapeutics will have a $1.86 EPS for FY2026, giving the stock an "Overweight" rating. 尽管最近一个季度的EPS为负值(0.47美元),但该公司击败了分析师的估计,并报告收入高于预期。 Despite a negative EPS of ($0.47) for the latest quarter, the company beat analysts' estimates and reported higher revenue than expected. 花旗集团已将其目标价下调至 32.00 美元，但维持“买入”评级，这表明尽管最近有内部人士抛售和 1,636.87% 的负股本回报率，但仍有可能增长。 Citigroup has lowered its price target to $32.00 but maintains a "buy" rating, indicating potential growth despite recent insider selling and a negative return on equity of 1,636.87%.